Company Overview of Protein Sciences Corporation
Protein Sciences Corporation develops, manufactures, and commercializes vaccines and biopharmaceuticals for the prevention and treatment of various diseases. The company offers Flublok, a recombinant protein-based seasonal influenza vaccine; Panblok, a pandemic influenza vaccine; FluNhance that is used to enhance additive to influenza vaccines; and SARS (D3252), a Severe Acute Respiratory Syndrome vaccine that is used to elicit neutralizing antibodies to the virus. It also provides Baculovirus Expression Vector System, a platform technology used for the development of a range of vaccines and therapeutics, such as prophylactic vaccines, therapeutic vaccines, gene therapy, and biologic applica...
1000 Research Parkway
Meriden, CT 06450
Founded in 1983
Key Executives for Protein Sciences Corporation
Chief Executive Officer, President and Director
Chief Administrative Officer, Senior Vice President and Corporate Secretary
Head of Government and Clinical Affairs
Executive Chairman and Global Head of Business Development
Compensation as of Fiscal Year 2014.
Protein Sciences Corporation Key Developments
Protein Sciences New York Facility Receives FDA Licensure to Manufacture Flublok®
May 13 15
Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration (FDA) licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok® influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology. The approval of its Pearl River facility accelerates the growth of Protein Sciences and Flublok.
Protein Sciences Corporation, UMN Pharma Inc. and IHI Corporation Enter into Agreement to Evaluate Sourcing Flublok® from Japan
Dec 22 14
Protein Sciences Corporation, UMN Pharma Inc. and IHI Corporation announced that they have entered into an agreement to assess the feasibility of sourcing the active ingredients of Flublok influenza vaccine from Japan. The drug substances would be manufactured at the Gifu (Japan) Plant of UNIGEN, a subsidiary of UMN Pharma in which IHI holds 50% of the common shares. UNIGEN manufactures Flublok for UMN Pharma at the 21,000L scale - ten times the scale the vaccine is manufactured in the United States. The Gifu plant has two 21,000L bioreactors and has the capacity to add six additional bioreactors. UMN holds a license from Protein Sciences for Flublok for the territories of Japan, China, Korea, Hong Kong, Taiwan and Singapore. UMN is partnered with Astellas to market Flublok in Japan.
Protein Sciences Corporation Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:00 PM
Dec 9 14
Protein Sciences Corporation Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:00 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 19, 2014